GHRP-2

GHS-R1a Agonism — The Ghrelin Receptor Pathway#

GHRP-2 is a synthetic hexapeptide agonist at the growth hormone secretagogue receptor (GHS-R1a) — the same pituitary and hypothalamic receptor that binds endogenous ghrelin. When it docks, the Gq-coupled receptor activates phospholipase-C, which kicks off IP3/DAG signalling and triggers intracellular calcium release in anterior-pituitary somatotrophs. The downstream result is a sharp, pulsatile release of stored GH — the same kind of pulse your body throws during deep sleep, just on demand.

This is why timing matters so much. GHRP-2 doesn't create a GH "bleed" — it fires a pulse. Stack that pulse on top of the natural stage-3 sleep pulse (pre-bed dose) or on top of a post-workout window and you're compounding biological events, not fighting them.

GHRH-Independent Somatotroph Activation#

The elegant part of GHRP-2's pharmacology — and the reason it stacks so well with GHRH analogs like Mod GRF 1-29 (CJC-1295 no-DAC) — is that it works through a completely separate pathway from GHRH. Patients with inactivating GHRH-receptor mutations, whose pituitaries cannot respond to GHRH at all, still mount a robust GH response to GHRP-2.

"Patients with an inactivating GHRH-receptor mutation demonstrated a 4.5-fold increase in GH release after GHRP-2, confirming GHRP-2 acts via a pathway independent of GHRH." — Roelfsema, F. et al., Journal of Clinical Endocrinology & Metabolism (2001)

GHRP-2 also suppresses somatostatin tone, removing the brake on GH release at the same time it steps on the gas. Combine a GHRP (gas + brake release) with a GHRH analog (separate gas pedal) and the pulses don't just add — they multiply.

"When administered together, GHRP and GHRH increased the GH response to more than the sum of individual responses. This synergism was significantly greater than additive." — Bowers, C.Y. et al., Journal of Clinical Endocrinology & Metabolism (1990)

Practical translation: running GHRP-2 solo is fine, but running it with Mod GRF 1-29 at matched 100 mcg doses is where the real GH AUC shows up — and it's the protocol almost every experienced user converges on.

GH Pulse → IGF-1 → Recomp#

The GH pulse itself has direct lipolytic effects (activating hormone-sensitive lipase in adipocytes, especially visceral fat) and acute insulin-antagonism that shifts substrate use toward fat oxidation during the ~2-hour pulse window. But the sustained physique changes — the slow lean-tissue gains, the skin and connective-tissue improvements, the recovery lift — come from hepatic IGF-1 production stimulated downstream of those pulses.

A typical 100/100 GHRP-2 + Mod GRF stack run 2×/day for 12 weeks produces a modest IGF-1 rise (roughly 20–40% over baseline in most users). That's meaningfully less than rhGH at bodybuilding doses, which is the honest answer to the GHRP-2 vs HGH question: this is a pulse-restorer, not an IGF-1 hammer. What you trade in magnitude, you get back in preserved physiology — endogenous pulsatility is retained, the negative feedback loops still function, and there's no shutdown to recover from.

Appetite, Prolactin, and Cortisol — The "Dirty" Part#

GHRP-2 is a ghrelin-receptor agonist, and ghrelin is the hunger hormone. Centrally, GHS-R1a activation in the arcuate nucleus drives NPY/AgRP neurons, producing real, noticeable hunger within 15–30 minutes of injection. For hard-gainers running a bulk, this is a feature. On a cut, it's the main reason some users switch to ipamorelin.

GHRP-2 also has meaningful cross-reactivity with prolactin and ACTH/cortisol release — the trade-off for its potent GH stimulation.

"GHRP-2 was able to stimulate a marked release of GH and to a lesser extent also PRL and ACTH/cortisol, with maximal effects observed after intravenous injection." — Arvat, E. et al., Peptides (1997)

At the 100 mcg saturation dose, the prolactin and cortisol bump is modest and clinically unremarkable for most users. Push to 200+ mcg per shot and you're paying for side effects (water retention, prolactin-driven libido blunting, cortisol edge) rather than buying more GH — the pituitary somatotroph pool is already near-maximally depleted by the saturation dose. This is the single most important dosing principle on this compound: more is not more.

Route, Kinetics, and Why Timing Is Everything#

GHRP-2 has a short plasma half-life (15–60 min) and a pharmacodynamic window of roughly two hours.

"Both subcutaneous and intramuscular administration of GHRP-2 produced nearly equivalent GH responses, with a rapid peak and return to baseline within about two hours." — Kitajima, S. et al., Domestic Animal Endocrinology (2000)

Subcutaneous and intramuscular routes produce near-identical GH AUCs at matched doses, so SC with a slin pin is the default. IV gives a sharper spike but desensitizes faster with repeat dosing. Intranasal works but delivers only ~1% of IV AUC — fine as a backup, not a primary route.

Three practical consequences drop out of this pharmacokinetic profile:

1. Empty stomach, always. Circulating glucose and free fatty acids blunt the somatotroph response. Give yourself a 20–30 min window clear of carbs/fat before and after each shot.
2. Space injections ≥3 hours apart so pulses don't fuse and so GHS-R1a has time to resensitize.
3. The pre-bed shot is the highest-leverage injection — it rides on top of the natural stage-3 GH pulse and improves sleep depth as a bonus. If you only run one shot a day, make it this one.

Common (most users)#

• Hunger spike — the signature GHRP-2 effect. Strong within 15–30 min of injection, fades over 60–90 min. On a bulk this is a feature; on a cut, either switch to ipamorelin or ride it out — tolerance builds partially over 1–2 weeks.
• Tingling / numbness in hands and feet — classic GH-pulse paresthesia, dose-dependent. Usually settles within the first 2 weeks. If persistent, drop per-shot dose to 100 mcg.
• Mild water retention / puffy face — cosmetic, resolves on cessation. Keep sodium reasonable and drop shots to 100 mcg if it becomes noticeable.
• Vivid dreams / deep sleep rebound — almost universal with pre-bed dosing. Not a problem; often the best-liked effect.
• Injection-site redness or itch — rotate sites, use fresh pins, ensure bac water is sterile.
• Transient lightheadedness or flush right after the shot — more common with IV, minimal with SC at 100 mcg.
• Post-shot lethargy — usually means you ate too close to the injection and blunted the pulse. Respect the 20–30 min fasted window before and after.

Uncommon (dose-dependent or individual)#

• Prolactin elevation — GHRP-2 raises prolactin meaningfully at 200+ mcg per shot. Watch for nipple sensitivity, libido drop, or difficulty achieving erection. Caber 0.25 mg twice weekly resolves it, or switch to ipamorelin.

"GHRP-2 was able to stimulate a marked release of GH and to a lesser extent also PRL and ACTH/cortisol, with maximal effects observed after intravenous injection." — Arvat et al., Peptides (1997)

• Cortisol / ACTH bump — same dose-response pattern as prolactin. At saturation dose (~100 mcg / 1 mcg/kg) the rise is small; above 200 mcg per shot it's measurable. Stay at saturation dose and you stay out of this zone.
• Fasting glucose creep — GH antagonizes insulin signaling. On long continuous cycles (12+ weeks) check fasting glucose and HbA1c. A small rise is expected; a big one means pull back or cycle off.
• Elevated IGF-1 above the reference range — pull bloods at ~8–12 weeks. If IGF-1 is above the age-adjusted top end, drop frequency.
• Tachyphylaxis with frequent dosing — GH response attenuates with repeated close-spaced doses. Space injections ≥3 h apart.

"Both subcutaneous and intramuscular administration of GHRP-2 produced nearly equivalent GH responses, with a rapid peak and return to baseline within about two hours." — Kitajima et al., Domestic Animal Endocrinology (2000)

• Carpal tunnel symptoms — rare at secretagogue doses, more of an rhGH issue, but possible if you're also running rhGH or stacking high-dose CJC-DAC. Back off if wrist/hand symptoms develop.

Rare but serious#

• Persistent hyperglycemia or new-onset insulin resistance — stop if fasting glucose climbs meaningfully or HbA1c crosses 5.7%. Reassess after washout.
• Worsening of pre-existing retinopathy — any visual changes, stop immediately.
• Significant gynecomastia from prolactin — rare at saturation dose, more plausible at chronic 200+ mcg 3×/day. Address with caber or switch compounds; do not ignore.
• Acromegalic changes (jaw/hand/foot growth, organ enlargement) — not realistic at secretagogue doses alone, but a concern for users running GHRP-2 on top of rhGH indefinitely. Cycle structure exists for a reason.

Hard contraindications#

• Active malignancy — GH and IGF-1 elevation is contraindicated. Do not run.
• Active diabetic retinopathy — GH worsens retinopathy. Do not run.
• Uncontrolled type 2 diabetes — get glycemic control first or skip this entirely.
• Pituitary tumors / acromegaly — do not stimulate a system that is already overproducing.
• Pregnancy and lactation — no safety data, do not run.

Gender and PCT considerations#

Non-hormonal, non-suppressive, and does not touch the HPTA — no PCT required for either sex. Women tolerate the same 100 mcg saturation dose men do; at 200+ mcg per shot, water retention and prolactin effects become more noticeable in women and aren't worth chasing. GHRP-2 slots cleanly alongside AAS cycles and into PCT as a recovery adjunct without complicating the hormonal picture.